Amylin Posts Lower Loss - Analyst Blog
October 21 2011 - 10:08AM
Zacks
Amylin Pharmaceuticals (AMLN) reported a net
loss of 7 cents per share in the third quarter of 2011, well below
the Zacks Consensus Estimate of a loss of 15 cents and the year-ago
loss of 31 cents. Higher revenues and lower expenses led to the
lower year-over-year loss.
Third quarter revenues, which included a $15 million milestone
payment, increased 12.1% to $175 million. Revenues exceeded the
Zacks Consensus Estimate of $166 million.
Quarterly Details
Quarterly revenues consisted of $155.1 million in product sales
(up 0.7%) and $19.9 million in collaborative revenues, which
consist of the amortization of upfront fees received under the
company's collaboration agreements with Eli Lilly
(LLY) and Takeda. Collaborative revenues included a $15 million
milestone payment from Lilly on the launch of Bydureon in the EU.
Collaborative revenues were $2.1 million in the year-ago
quarter.
Product revenues comprised $128.1 million in sales of Byetta
(exenatide) and $27.0 million in sales of Symlin. While Byetta
revenues declined 3.2% from the year-ago period, Symlin increased
25% from the year-ago period.
We note that Byetta revenues declined 0.7% sequentially. The
slight decrease in revenue was due to a 4.5% decline in
prescription volume that was partially offset by price increases.
Byetta revenues have been under pressure over the past few quarters
due to pancreatitis fears associated with the use of the drug.
Competition has also increased with the entry of Novo
Nordisk’s (NVO) Victoza. Amylin is looking to return
Byetta to growth now that it is armed with FDA approval for the use
of the drug as a first-line monotherapy for type II diabetes
patients.
Byetta should also benefit from the recent FDA approval under
which Byetta can be used in combination with
Sanofi-Aventis’ (SNY) Lantus (insulin glargine),
with or without metformin and/or a TZD, for the treatment of type
II diabetes in patients who are not achieving adequate glycemic
control on Lantus alone.
Selling, general and administrative (SG&A) expenses for the
quarter declined to $63.1 million from $70.0 million in the
year-earlier period. The decrease was mainly due to efficiencies
driven by the company's reduced cost structure and lower costs
associated with pre-Bydureon launch activities.
Research and development (R&D) expenses declined to $46.6
million in the reported quarter from $51.2 million reported in the
prior-year period. The decline primarily reflects lower Bydureon
pre-launch stock manufacturing which was partially offset by higher
spending on the metreleptin program.
2011 Guidance Reflects Tight Cost Control
For 2011, Amylin now expects non-GAAP operating results to be
close to breakeven. Earlier, Amylin was expecting an operating loss
of $15 million to $25 million.
Amylin expects to receive tiered royalties of less than $5
million on ex-US sales of exenatide in 2011.
Bydureon Update
Amylin provided an update on Bydureon (a once-weekly version of
Byetta), which gained EU approval in June 2011. Amylin and its
partners, Eli Lilly and Alkermes, Inc. (ALKS), are
looking to get Bydureon approved in the US for the treatment of
type II diabetes.
Bydureon, which has already received two complete response
letters from the FDA, is currently under FDA review with a final
response expected by January 28, 2012. Amylin is working on
pre-launch activities for Bydureon.
Bydureon is currently available in the UK and Germany. Although
it’s early days for the Bydureon EU launch, Amylin reported that
initial demand in the wholesale channels is encouraging so far.
Moreover, the National Institute of Clinical Health and
Excellence (NICE) which oversees the reimbursement of medications
in the UK, issued a preliminary recommendation to reimburse
Bydureon when used in combination with metformin and/or a
thiazolidinedione (TZD) or a sulfonylurea. The final recommendation
will be out in February 2012. This could help boost adoption of
Bydureon.
As far as the suspension formulation of Bydureon is concerned,
Amylin intends to meet with regulatory authorities by the end of
the year to decide on the design of pivotal studies for both the
weekly and monthly exenatide formulations. The pen device for
Bydureon remains under development with a launch expected in late
2012/early 2013.
However, we were disappointed to hear about the delay in the
completion of the submission of a rolling Biologics License
Application (BLA) obesity candidate, metreleptin. Amylin is looking
to get metreleptin approved for the treatment of diabetes and/or
hypertriglyceridemia in patients suffering from rare forms of
lipodystrophy. The company, which was aiming to finish filing the
BLA by the end of 2011, now expects to complete the same in the
first half of 2012. The company attributed the delay to capacity
issues with its contract manufacturer and complexities encountered
during the validation runs.
Neutral on Amylin
We currently have a Neutral recommendation on Amylin. Going
forward, we expect investor focus to remain on Byetta’s performance
and updates on the US approval process for Bydureon.
ALKERMES INC (ALKS): Free Stock Analysis Report
AMYLIN PHARMA (AMLN): Free Stock Analysis Report
LILLY ELI & CO (LLY): Free Stock Analysis Report
NOVO-NORDISK AS (NVO): Free Stock Analysis Report
SANOFI-AVENTIS (SNY): Free Stock Analysis Report
Zacks Investment Research
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Apr 2024 to May 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From May 2023 to May 2024